Cortexyme announces agreement to acquire novosteo

South san francisco, calif.--(business wire)---- $crtx--cortexyme, inc. (nasdaq: crtx), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases, today announced that it entered into an agreement under which the company plans to acquire novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury. upon completion of the transaction, novosteo stockholders will own appr
QNCX Ratings Summary
QNCX Quant Ranking